Company / Shareholders' Equity
Ventyx Biosciences, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$254.0M
FY2024
5-year range
-$30.7M / $353.9M
FY2020-FY2024
Trend
+4.1%
vs FY2023
Sector context
#143 of 214
Health Care
What the data says
At $254M, Ventyx Biosciences, Inc.'s shareholders' equity ranks #143 of 214 in the Health Care sector. Declined from $354M to $254M over the past 2 years.
Based on SEC 10-K filings.
$254M in FY2024 with a 3-year CAGR of -3.1%.
Declined from $354M to $254M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#143 of 214 in Health CareTop 67% of 214This company $254.0M Sector average $2.6B
▼
-90.1% below sector average
Key checks
Key Insights
- 3-year CAGR of -3.1%, indicating a declining trend.
- In FY2024, shareholders' equity increased 4.1% year-over-year.
- Ranks #143 out of 214 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 3.63 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $254.0M | +4.1% |
| FY2023 | $243.9M | -31.1% |
| FY2022 | $353.9M | +26.8% |
| FY2021 | $279.2M | +1010.8% |
| FY2020 | -$30.7M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026